Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - Nauck, M A; D‘Alessio, D A (Cardiovasc Diabetol, 2022)